Skip to main content
Signal8
Launch Terminal

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc.

NASDAQ:VKTXHealthcare
+1.56%$27.28
AH$26.88-1.47%vs close
Mkt Cap$3.48B
Float112.06M
O/S127.52M
Vol
$ Vol
RVOL
Inst Own59.2%
SI22.8%
Earnings
Dilution
Viking Therapeutics, Inc. logoNASDAQ:VKTX$27.28+1.56%
Upcoming Catalysts
  • VK2735READOUT
    Cash runway at this date: -5mo
    2027~60wPR
Phase Distribution
13 lead-sponsored trials·4 active·7 completed
Phase 14
Phase 25
Phase 34

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

    VK2735

    Weight Loss

    Enrollment
    1,100
    Start
    Jun 2025
    Primary Completion
    Jul 2027est.
    Completion
    Aug 2027est.
    NCT07104383
  • Phase 3
    Active, not recruiting

    VK2735 for Weight Management Phase 3

    VK2735

    Weight Loss

    Enrollment
    4,500
    Start
    Jun 2025
    Primary Completion
    Jul 2027est.
    Completion
    Aug 2027est.
    NCT07104500
  • Phase 3
    Not yet recruiting

    Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

    VK2735, Placebo comparator

    Weight Loss

    Enrollment
    560
    Start
    Nov 2026est.
    Primary Completion
    Jul 2028est.
    Completion
    Aug 2028est.
    NCT07868835
  • Phase 3
    Not yet recruiting

    Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

    VK2735 Oral, Placebo Comparator

    Weight Loss

    Enrollment
    560
    Start
    Nov 2026est.
    Primary Completion
    Oct 2028est.
    Completion
    Dec 2028est.
    NCT07868939
  • Phase 2
    Completed

    Acute Hip Fracture Study in Patients 65 Years or Greater

    VK5211, Placebo

    Hip Fractures

    Enrollment
    108
    Start
    Oct 2015
    Primary Completion
    Nov 2017
    Completion
    Dec 2017
    NCT02578095
  • Phase 2
    Completed

    Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

    VK2809, Placebo

    Hyperlipidemia, NAFLD

    Enrollment
    59
    Start
    Sep 2016
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT02927184
  • Phase 2
    Completed

    A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

    VK2809, Placebos

    NASH - Nonalcoholic Steatohepatitis

    Enrollment
    248
    Start
    Nov 2019
    Primary Completion
    May 2023
    Completion
    Jan 2024
    NCT04173065
  • Phase 2
    Completed

    VK2735 for Weight Management Phase 2

    VK2735, Placebo

    Weight Loss

    Enrollment
    176
    Start
    Aug 2023
    Primary Completion
    Feb 2024
    Completion
    Apr 2024
    NCT06068946
  • Phase 2
    Completed

    VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

    Placebo, VK2735

    Weight Loss

    Enrollment
    280
    Start
    Dec 2024
    Primary Completion
    Jun 2025
    Completion
    Aug 2025
    NCT06828055
  • Phase 1
    Completed

    A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

    VK0214

    Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

    Enrollment
    24
    Start
    Jun 2021
    Primary Completion
    Oct 2024
    Completion
    Nov 2024
    NCT04973657
  • Phase 1
    Completed

    Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

    VK2735, Placebo

    Weight Loss, NASH

    Enrollment
    92
    Start
    Dec 2021
    Primary Completion
    Nov 2024
    Completion
    Dec 2024
    NCT05203237
  • Phase 1
    Recruiting

    A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

    VK2735 Drug, Placebo

    Obese Adults

    Enrollment
    270
    Start
    Nov 2025
    Primary Completion
    May 2027est.
    Completion
    Jul 2027est.
    NCT07838740
  • Phase 1
    Recruiting

    A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

    SC VK3019, Matching placebo

    Obese Adults

    Enrollment
    56
    Start
    Jul 2026
    Primary Completion
    Oct 2026est.
    Completion
    Nov 2026est.
    NCT07846033
Search ClinicalTrials.gov for “Viking Therapeutics”